AstraZeneca, Others Hit With Nexium Pay-For-Delay Suits

Law360, New York (August 27, 2012, 7:04 PM EDT) -- Three putative class actions filed Friday in Pennsylvania federal court accuse AstraZeneca PLC and several generic-drug makers of violating antitrust laws by entering agreements to delay entry of a generic version of AstraZeneca's heartburn drug Nexium.

The actions — one filed with the insurance trust fund of the Miami Fraternal Order of Police Lodge 20 serving as lead plaintiff, another with the health benefits fund of the New York Hotel Trades Council & Hotel Association of New York City Inc. as lead plaintiff, and a third...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.